Hygiene EducationHealth Education
Darzalex® is a monoclonal antibody that targets to the protein called CD38, which is highly expressed on multiple myeloma cells. Once Darzalex® attaches to CD38, it induces rapid cell death and activates the immune system to destroy the myeloma cells.
Daunorubicin is classified as an anthracyline antibiotic. This medicine inhibits DNA synthesis by producing DNA cross-links which halt cell replication and eventually cause cell death. This cell damage slows or stops the growth of cancer cells in the body.
Atezolizumab is a monoclonal antibody that binds to PD-L1 (programmed cell death ligand 1) and blocks its interaction with PD-1 (programmed cell death 1 receptor).
Blinatumomab is a bispecific T-cell receptor-engaging (BiTE) antibody that binds to CD19 expressed on B cells and CD3 expressed on T cells.
Epirubicin is classified as an anthracyline antibiotic. This medicine inhibits DNA synthesis by producing DNA cross-links which halt cell replication and eventually cause cell death.
Eribulin is a synthetic product derived from a natural substance found in a sea sponge. This medicine inhibits the function of microtubules for cell division, thus stopping cancer cells from separating into two new cells, eventually causing cell death.
Fludarabine is classified as an anticancer antimetabolites. This drug inhibiting DNA polymerase that is essential for the replication of DNA and RNA.
Besponsa® is an antibody-drug conjugate combining a cytotoxic agent called calicheamicin with a monoclonal antibody, which targets a protein called CD22 on the surface of B cells.
Ipilimumab is a monoclonal antibody that binds to CTLA-4 (human cytotoxic T lymphocyte-associated antigen 4) on T cells. By blocking CTLA-4, ipilimumab helps strengthen the immune system by promoting the function and growth of T cells, thereby enhancing the immune system against cancer cells.
Trastuzumab is a monoclonal antibody which targets the human epidermal growth factor receptor 2 (HER2) on cells. HER2 is found in large amounts on the surface of breast cancer cells, resulting in tumors growing more quickly. By attaching to the HER2 receptor, trastuzumab blocks HER2 from receiving growth signals, preventing further cancer growth and slowing cancer progression.